Corn protein source bioactive peptide as well as screening method and application thereof
By extracting and purifying the bioactive peptide from the corn protein powder, the problem of insufficient utilization of high added value of corn protein powder in the prior art is solved, and a safe and efficient DPP-IV inhibitor is provided, and a significant lowering of blood sugar is achieved.
Patent Information
- Application Number
- CN202510444932.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-09
- Publication Date
- 2025-07-08
AI Technical Summary
The prior art lacks bioactive peptides with blood sugar-lowering function using corn protein powder as raw material, and there is a lack of blood sugar-lowering products with corn protein-derived bioactive peptides as the main component on the market. There is a risk of adverse reactions in chemical synthesis of DPP-IV inhibitors.
The zein-derived bioactive peptides, including LPGF, LPFN, SPFLGQ, NPF, LPPFS, LPPFNQ, VPPPVHL and LPPYLSP, were extracted and purified from corn protein powder, and the zein proteolytic solution with significant DPP-IV inhibitory activity was prepared by enzymatic lysis, anion exchange chromatography and reverse phase chromatography separation.
The obtained zein-derived bioactive peptide showed significant DPP-IV inhibitory activity and blood glucose-lowering effect, with an IC50 value ranging from 0.0617 mg/mL to 1.3582 mg/mL, providing a safe and effective blood glucose-lowering solution.
Smart Images

Figure CN120271661A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of corn protein-derived bioactive peptides, and particularly relates to a corn protein-derived bioactive peptide, a screening method thereof and an application thereof. Background Art
[0002] Diabetes, as a chronic metabolic disease, seriously threatens human health. Diabetes can not only cause a series of complications, such as retinopathy, neuropathy, kidney disease and cardiovascular diseases, greatly reducing the quality of life of patients, but also bringing a heavy burden to the social medical system. In the field of diabetes treatment, dipeptidyl peptidase-4 (DPP-IV) has become an important drug target. DPP-IV can rapidly degrade glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP are incretins and play a key role in the process of blood glucose regulation. They can stimulate insulin secretion, inhibit glucagon release, and delay gastric emptying, thereby reducing blood glucose levels. When DPP-IV is overexpressed, the action time of GLP-1 and GIP is significantly shortened, weakening the effect of blood glucose regulation. At present, a variety of DPP-IV inhibitors, such as sitagliptin, saxagliptin, etc., have been developed clinically for the treatment of type 2 diabetes. However, during the long-term use of these chemically synthesized DPP-IV inhibitors, they may cause adverse reactions such as headache, upper respiratory tract infection, nausea, diarrhea, etc., and some patients may also have severe allergic reactions. Therefore, searching for safe and effective natural DPP-IV inhibitors has become a research hotspot in the field of diabetes treatment.
[0003] Bioactive peptides are a class of small protein fragments with special physiological functions. Due to their advantages of high efficiency, low toxicity, easy absorption, etc., they show great potential in the field of diabetes treatment. Numerous studies have shown that bioactive peptides extracted from different biological resources can play a hypoglycemic role through various pathways, and inhibiting the activity of DPP-IV is one of the important mechanisms. Compared with chemically synthesized drugs, bioactive peptides have better safety and biocompatibility, and can effectively reduce the risk of adverse reactions.
[0004] Corn is an important food crop with rich yields. Corn protein is the main by-product in the process of corn processing, with a wide source and low cost. However, for a long time, the application of corn protein has been limited to the feed industry, and its high-value utilization is restricted. At present, there is still a lack of relevant research on further preparing bioactive peptides with hypoglycemic functions from corn protein powder in this field, and there is also a lack of hypoglycemic products mainly composed of corn protein-derived bioactive peptides in the market. Summary of the Invention
[0005] In view of this, one of the purposes of the present invention is to provide a corn protein-derived bioactive peptide, a screening method thereof and an application thereof, which are derived from corn gluten meal.
[0006] Another purpose of the present invention is to provide a corn protease hydrolysate containing the above-mentioned corn protein-derived bioactive peptide, a preparation method thereof and an application thereof.
[0007] In order to achieve the above-mentioned invention purposes, the present invention provides the following technical solutions:
[0008] The present invention provides a corn protein-derived bioactive peptide, which comprises at least one of LPGF (SEQ ID NO.1), LPFN (SEQ ID NO.2), SPFLGQ (SEQ ID NO.3), NPF, LPPFS (SEQ ID NO.4), LPPFNQ (SEQ ID NO.5), VPPPVHL (SEQ ID NO.6) and LPPYLSP (SEQ ID NO.7).
[0009] The present invention also provides a corn protease hydrolysate, which contains the above-mentioned corn protein-derived bioactive peptide.
[0010] The present invention also provides a preparation method of the above-mentioned corn protease hydrolysate, which comprises the following steps: mixing corn gluten meal with neutral protease for enzymatic hydrolysis, centrifuging to obtain the supernatant, and obtaining the corn protease hydrolysate; the temperature of the enzymatic hydrolysis is 45 °C, the time of the enzymatic hydrolysis is 157 min, and the pH of the enzymatic hydrolysis is 7.0; the dosage of the neutral protease is 640 U / g protein based on the protein mass in the corn gluten meal.
[0011] The present invention has no special limitation on the specific sources of the corn gluten meal and the neutral protease, and conventional commercially available products in the art can be used. In the present invention, the corn gluten meal is preferably corn gluten meal that has been extruded and puffed and has had its starch removed. The present invention has no special limitation on the specific operations of extrusion and starch removal, and the corn gluten meal that has been extruded and puffed and has had its starch removed can be obtained by commercial purchase. In the present invention, before enzymatic hydrolysis, it is preferably further included the step of mixing the corn gluten meal with water to prepare a suspension, and the mass concentration of the suspension is preferably 10% (based on protein). In the present invention, after enzymatic hydrolysis, it is preferably necessary to perform enzyme inactivation treatment and then centrifuge. The temperature of the enzyme inactivation treatment is preferably 100 °C; the time of the enzyme inactivation treatment is preferably 10 min to inactivate the activity of the neutral protease. In the present invention, the rotation speed of the centrifugation is preferably 8000 r / min, and the time of the centrifugation is preferably 15 min.
[0012] The present invention also provides a method for screening bioactive peptides from corn protein sources. On the basis of the above preparation method, the method further includes the following steps: performing anion exchange chromatography separation on the permeate, collecting the fraction with the highest DPP-IV inhibitory activity to obtain an anion exchange chromatography solution; performing reverse phase chromatography separation on the anion exchange chromatography solution, and collecting the fraction with the highest DPP-IV inhibitory activity, which is the bioactive peptide from corn protein sources. The bioactive peptide from corn protein sources includes the amino acid sequence NPF and at least one bioactive peptide from corn protein sources shown in SEQ ID NO.1 to SEQ ID NO.7.
[0013] In the present invention, the ion exchanger for the anion exchange chromatography separation is preferably Q-Sepharose TM FastFlow strong anion exchanger, and the eluent is preferably 20 mmol / L Tris-HCl containing 1 mol / mL NaCl. The pH of the Tris-HCl is preferably 9.5, and the flow rate is preferably 2 mL / min. In the present invention, the reverse phase chromatography separation preferably includes semi-preparative reverse phase chromatography separation first and then analytical reverse phase chromatography separation.
[0014] In the present invention, the column type for the semi-preparative reverse phase chromatography separation is preferably XSelect CSH C18 OBD Prep Column; the mobile phase for the semi-preparative reverse phase chromatography separation preferably includes mobile phase A and mobile phase B. Mobile phase A is preferably an aqueous solution of 2% acetonitrile containing 0.065 vol% TFA, and mobile phase B is preferably an aqueous solution of 80% acetonitrile containing 0.05 vol% TFA. In the present invention, the column type for the analytical reverse phase chromatography separation is preferably XSelect Peptide CSH C18 Column; the mobile phase for the analytical reverse phase chromatography separation preferably includes mobile phase A and mobile phase B. Mobile phase A is preferably an aqueous solution of 2% acetonitrile containing 0.065 vol% TFA, and mobile phase B is preferably an aqueous solution of 100% acetonitrile containing 0.05 vol% TFA. The present invention has no special limitation on the specific sources of the above raw materials.
[0015] The present invention also provides the application of the above bioactive peptide from corn protein sources, the above corn protease hydrolysate, the above preparation method or the above method for screening bioactive peptides from corn protein sources in the preparation of products for inhibiting DPP-IV activity or in the preparation of hypoglycemic products. The products preferably include drugs.
[0016] The present invention also provides the application of the above bioactive peptide from corn protein sources, the above corn protease hydrolysate, the above preparation method or the above method for screening bioactive peptides from corn protein sources in the preparation of products for helping to maintain a healthy blood glucose level. The products preferably include drugs or foods.
[0017] Advantages of the present invention:
[0018] For the first time, the present invention isolates and purifies a corn protein-derived bioactive peptide from corn protein powder, which has a significant inhibitory effect on DPP-IV activity and a blood sugar-lowering effect. Among them, the IC 50 of LPGF for inhibiting DPP-IV is 0.0617 mg / mL, and the IC 50 of LPFN for inhibiting DPP-IV is 0.0841 mg / mL, the IC 50 of SPFLGQ for inhibiting DPP-IV is 0.1472 mg / mL, the IC 50 of NPF for inhibiting DPP-IV is 0.2731 mg / mL, the IC 50 of LPPFS for inhibiting DPP-IV is 0.5727 mg / mL, the IC 50 of LPPFNQ for inhibiting DPP-IV is 0.8473 mg / mL, the IC 50 of VPPPVHL for inhibiting DPP-IV is 1.1340 mg / mL, and the IC 50 of LPPYLSP for inhibiting DPP-IV is 1.3582 mg / mL. Description of the drawings
[0019] Figure 1 is the elution profile of ion exchange chromatography separation;
[0020] Figure 2 is the DPP-IV inhibition result of the elution peak of ion exchange chromatography separation. Among them, if the superscript letters of any two components are the same, it indicates that the DPP-IV inhibition rates of the two groups do not have a significant difference, p > 0.05. If the superscript letters of any two components are different, it indicates that the DPP-IV inhibition rates of the two groups have a significant difference, p < 0.05;
[0021] Figure 3 is the elution profile of semi-preparative reverse phase chromatography;
[0022] Figure 4 is the DPP-IV inhibition result of the elution peak of semi-preparative reverse phase chromatography. Among them, if the superscript letters of any two components are the same, it indicates that the DPP-IV inhibition rates of the two groups do not have a significant difference, p > 0.05. If the superscript letters of any two components are different, it indicates that the DPP-IV inhibition rates of the two groups have a significant difference, p < 0.05;
[0023] Figure 5 is the elution profile of analytical reverse phase chromatography;
[0024] Figure 6To analyze the DPP-IV inhibition results of the elution peaks in reversed-phase chromatography, if the superscript letters of any two components are the same, it indicates that there is no significant difference in the DPP-IV inhibition rates of these two groups, p > 0.05. If the superscript letters of any two components are different, it indicates that there is a significant difference in the DPP-IV inhibition rates of these two groups, p < 0.05. Detailed implementation mode
[0025] The technical solutions provided by the present invention will be described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0026] In the following embodiments, unless otherwise specified, all are conventional methods.
[0027] In the following embodiments, the materials, reagents, etc. used, unless otherwise specified, can all be obtained from commercial channels.
[0028] Example 1
[0029] A bioactive peptide derived from corn protein is prepared as follows:
[0030] 1. Preparation of corn protein hydrolysate:
[0031] Mix the extruded and starch-removed corn protein powder (purchased from Jingliang Longjiang Bioengineering Co., Ltd.) with water to prepare a suspension with a substrate concentration of 10% (m / v). Adjust the pH of the suspension to 7.0, then add neutral protease (Neutrase 0.8L) (purchased from Novozymes (China) Biotechnology Co., Ltd.). Based on the protein mass in the corn protein powder, the enzyme addition amount is 640 U / g protein. React at 45°C for 157 min. After the enzymatic hydrolysis is completed, heat the hydrolysate at 100°C for 10 min to inactivate the neutral protease activity, then centrifuge at 8000 r / min for 15 min, discard the precipitate, and take the supernatant to obtain the corn protein hydrolysate.
[0032] 2. Ion exchange chromatography separation
[0033] Filter the corn protein hydrolysate obtained in step 1 through a 0.22 μm microporous filter membrane, and perform Q-Sepharose TM Fast Flow strong anion exchange chromatography Initial buffer: 20 mmol / L pH 9.5 Tris-HCl buffer, eluent: 20 mmol / L pH 9.5 Tris-HCl buffer containing 1 mol NaCl, gradient elution for 170 min, flow rate: 2 mL / min, detect at UV 214 nm. Measure the inhibitory activity (hypoglycemic activity) of DPP-IV for each tube of collected solution. The method for measuring the inhibitory activity of DPP-IV is as follows:
[0034] Mix 40 μL of the sample solution (1 mg / mL) with 10 μL of the DPP-IV (100 ng / mL) solution and react at 37 °C for 10 min. Then add 50 μL of the substrate Gly-Pro-PNA (from Sigma-Aldrich, USA) (concentration 100 μM) and continue to react at 37 °C for 1 h. After the reaction, measure the absorbance at a wavelength of 405 nm. Conduct three parallel tests and calculate the inhibitory activity of the sample against DPP-IV (also known as the DPP-IV inhibition rate) using the following formula:
[0035] Inhibitory DPP-IV activity % = [[(A c - A cb ) - (A s - A sb )] / (A c - A cb )] × 100%
[0036] In the formula, A s : Absorbance when adding enzyme and sample; A sb : Absorbance of the sample blank (sample, buffer, substrate); A c : Absorbance of the control (enzyme, substrate, buffer); A cb : Absorbance of the control blank (buffer, substrate).
[0037] The elution profiles of ion exchange chromatography separation and the DPP-IV inhibition results of each peak are shown in Figure 1 and Figure 2 respectively. According to the results in Figure 1 and Figure 2 , collect the fraction with the strongest hypoglycemic function in the elution peak for standby, i.e., fraction 3.
[0038] 3. Reverse-phase chromatography separation
[0039] 3.1 Determine the active region of the zein-derived bioactive peptide with DPP-IV inhibitory activity using a semi-preparative reverse-phase chromatography column
[0040] Weigh 5 mg of the active fraction obtained in step 2 (fraction number 3 in Figure 2 ) and dissolve it in 5 mL of 2% aqueous acetonitrile solution. Filter it through a 0.22 μm microporous filter membrane. The model of the chromatography column is XSelect CSH C18 OBD PrepColumn, ( 10 μm), detection wavelength 214 nm, flow rate 1 mL / min, mobile phase A is 2 vol% acetonitrile aqueous solution containing 0.065 vol% TFA, mobile phase B is 80 vol% acetonitrile aqueous solution containing 0.05 vol% TFA, gradient elution for 80 min, and the elution program is shown in Table 1 below. The elution profile of semi-preparative reversed-phase chromatography is as Figure 3 shown. Each fraction eluting from the column was collected and the DPP-IV inhibitory activity of each tube of sample was determined. The determination method was the same as the DPP-IV inhibitory activity determination method described in Step 2. The DPP-IV inhibition results of each peak are as Figure 4 and Table 2 show.
[0041] Table 1 Gradient elution program of semi-preparative reversed-phase chromatography
[0042] Time / min A / % B / % 0 98 2 30 75 25 72 55 45 75 2 98 78 2 98 80 98 2
[0043] Table 2 DPP-IV inhibition results of the elution peaks of semi-preparative reversed-phase chromatography
[0044] Semi-preparative RP-HPLC elution peak DPP-IV inhibition rate (%) 1 12.36±1.22 2 79.54±2.17 3 87.32±3.12 4 90.34±2.56 5 93.42±1.72
[0045] According to Figure 4 and Table 2, it can be determined that the active fraction with the highest hypoglycemic activity is in the 5th tube.
[0046] 3.2 Separation of DPP-IV inhibitory active zein-derived bioactive peptides by analytical reversed-phase chromatography column
[0047] The active fraction in the 5th tube obtained in Step 3.1 was dissolved in 2% acetonitrile aqueous solution and further separated and purified using an analytical column. The column type of the analytical column is XSelect Peptide CSH C18 Column, ( 3.5 μm), detection wavelength 214 nm, flow rate 1 mL / min, sample loading volume 20 μL. Mobile phase A is 2% acetonitrile aqueous solution containing 0.065 vol% TFA, and mobile phase B is 100% acetonitrile aqueous solution containing 0.05 vol% TFA. The gradient elution program is shown in Table 3. The elution profile of analytical reversed-phase chromatography is as Figure 5 shown.
[0048] Table 3 Gradient elution program of analytical reversed-phase chromatography
[0049] Time / min A / % B / % 0 100 2 30 60 40 35 0 100 40 0 100
[0050] From Figure 5It can be seen that after the components are separated by the analytical column, 3 zein peptide components are obtained. The peak tips of each peak are collected for DPP-IV inhibitory activity determination, and the determination method is the same as the DPP-IV inhibitory activity determination method described in step 2. The DPP-IV inhibition results of each peak are as Figure 6 shown in Table 4.
[0051] Table 4 DPP-IV inhibition results of the elution peaks of analytical RP chromatography
[0052] Analytical RP-HPLC elution peak DPP-IV inhibition rate (%) 1 45.12±1.95 2 60.24±1.76 3 20.37±1.52
[0053] From Figure 6 and the results in Table 4, it can be determined that peak 2 is the component with the highest hypoglycemic activity and is a zein-derived bioactive peptide. Peak 2 is freeze-dried for standby mass spectrometry sequencing.
[0054] 4. Sequencing
[0055] The peak 2 with the highest activity separated in step 3.2 is sequenced, and the sequences of the zein-derived DPP-IV inhibitory peptides are Leu-Pro-Gly-Phe (LPGF), Leu-Pro-Phe-Asn (LPFN), Ser-Pro-Phe-Leu-Gly-Gln (SPFLGQ), Asn-Pro-Phe (NPF), Leu-Pro-Pro-Phe-Ser (LPPFS), Leu-Pro-Pro-Phe-Asn-Gln (LPPFNQ), Val-Pro-Pro-Pro-Val-His-Leu (VPPPVHL), and Leu-Pro-Pro-Tyr-Ser-Pro (LPPYLSP) respectively. The number of amino acids is 4, 4, 6, 3, 5, 6, 7, and 7 respectively, and the molecular weights are 432.51 Da, 489.57 Da, 647.72 Da, 376.41 Da, 559.66 Da, 714.81 Da, 757.93 Da, and 785.93 Da respectively.
[0056] Example 2
[0057] According to the mass spectrometry sequencing results in Example 1, the zein-derived bioactive peptides LPGF, LPFN, SPFLGQ, NPF, LPPFS, LPPFNQ, VPPPVHL, and LPPYLSP are chemically synthesized (entrusted to Shanghai Qiangyao Biotechnology Co., Ltd. for synthesis), and the DPP-IV inhibitory abilities of the above zein-derived bioactive peptides are measured respectively. The measurement method is the same as the DPP-IV inhibitory activity determination method described in step 2 of Example 1. The results show that the polypeptides LPGF, LPFN, SPFLGQ, NPF, LPPFS, LPPFNQ, VPPPVHL, and LPPYLSP inhibit the IC of DPP-IV50 They are 0.0617 mg / mL, 0.0841 mg / mL, 0.1472 mg / mL, 0.2731 mg / mL, 0.5727 mg / mL, 0.8473 mg / mL, 1.1340 mg / mL, and 1.3582 mg / mL respectively. From the above results, it can be concluded that the DPP-IV activity inhibitory peptide prepared by the present invention has high hypoglycemic activity.
[0058] The above description is only a preferred embodiment of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and refinements can be made, and these improvements and refinements should also be regarded as the protection scope of the present invention.
Claims
1. A bioactive peptide from corn protein source, characterized in that, The corn protein-derived bioactive peptide includes the amino acid sequence NPF and at least one of those shown in SEQ ID NO.1 to SEQ ID NO.
7.
2. A corn protease hydrolysate, characterized in that, The corn protein hydrolysate contains the corn protein-derived bioactive peptide described in claim 1.
3. The preparation method of the corn protease hydrolysate according to claim 2, characterized in that, It includes the following steps: mixing corn protein powder with neutral protease for enzymatic hydrolysis, centrifuging to obtain the supernatant to get the corn protein hydrolysate; the temperature of the enzymatic hydrolysis is 45°C, the time of the enzymatic hydrolysis is 157 min, the pH of the enzymatic hydrolysis is 7.0; the dosage of the neutral protease is 640 U / g protein based on the protein mass in the corn protein powder.
4. A method for screening bioactive peptides from corn protein sources, characterized in that, Based on the preparation method described in claim 3, it further includes the following steps: performing anion exchange chromatography separation on the permeate, collecting the fraction with the highest DPP-IV inhibitory activity to obtain the anion exchange chromatography solution; performing reverse phase chromatography separation on the anion exchange chromatography solution, collecting the fraction with the highest DPP-IV inhibitory activity, which is the corn protein-derived bioactive peptide, and the corn protein-derived bioactive peptide includes the corn protein-derived bioactive peptide described in claim 1.
5. The method according to claim 4, wherein The ion exchanger for anion exchange chromatography separation is Q-Sepharose TM FastFlow strong anion exchanger, the eluent is 20 mmol / L Tris-HCl containing 1 mol / mL NaCl, the pH of the Tris-HCl is 9.5, and the flow rate is 2 mL / min.
6. The method according to claim 4, characterized in that, The reverse phase chromatography separation is first performed by semi-preparative reverse phase chromatography separation and then by analytical reverse phase chromatography separation.
7. The method according to claim 6, wherein The column type of the semi-preparative reverse phase chromatography separation is XSelect CSH C18 OBD Prep Column; the mobile phase of the semi-preparative reverse phase chromatography separation includes mobile phase A and mobile phase B, mobile phase A is a 2 vol% acetonitrile aqueous solution containing 0.065 vol% TFA, and mobile phase B is an 80 vol% acetonitrile aqueous solution containing 0.05 vol% TFA.
8. The method according to claim 6, wherein The column type of the analytical reverse phase chromatography separation is XSelectPeptide CSH C18 Column; the mobile phase of the analytical reverse phase chromatography separation includes mobile phase A and mobile phase B, mobile phase A is a 2 vol% acetonitrile aqueous solution containing 0.065 vol% TFA, and mobile phase B is a 100 vol% acetonitrile aqueous solution containing 0.05 vol% TFA.
9. Use of any one of the following in the preparation of a product for inhibiting DPP-IV activity or in the preparation of a hypoglycemic product, characterized in that, (1) The corn protein-derived bioactive peptide described in claim 1; (2) The corn protein hydrolysate described in claim 2; (3) The preparation method described in claim 3; (4) The method described in any one of claims 4 to 8.
10. Use of any one of the following in the preparation of a product for helping to maintain a healthy blood glucose level, characterized in that, (1) The corn protein-derived bioactive peptide described in claim 1; (2) The corn protein hydrolysate described in claim 2; (3) The preparation method described in claim 3; (4) The method described in any one of claims 4 to 8.
